## UHS: Universal Health Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.5% below STRENGTH zone (4.0-10.0%); PEG 1.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($218.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Arrowstreet Capital Limited Partnership Cuts Position in Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251204T020951 | Neutral | Relevance: 100%
- Arrowstreet Capital Limited Partnership reduced its stake in Universal Health Services (NYSE:UHS) by 13.8% in Q2, selling 173,532 shares, but still holds over a million shares valued at approximately $196.6 million. Despite this reduction, other large institutional investors like Virginia Retirement Systems and Norges Bank initiated new positions, maintaining institutional ownership around 86.05%. The company reported strong Q2 earnings with EPS significantly beating estimates and declared a quarterly dividend of $0.20 per share.

**2. Distillate Capital Partners LLC Trims Position in Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251203T041039 | Somewhat-Bullish | Relevance: 100%
- Distillate Capital Partners LLC reduced its stake in Universal Health Services (NYSE:UHS) by 5.5% in Q2, selling 4,477 shares, though institutional ownership remains high at 86.05%. Despite this, several other institutions significantly increased their positions. Universal Health Services reported strong quarterly earnings, beating estimates, declared a quarterly dividend, and holds a consensus "Hold" rating with a target price of $232.64.

**3. Norges Bank Purchases Shares of 460,024 Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251205T113642 | Somewhat-Bullish | Relevance: 97%
- Norges Bank acquired a new position of 460,024 shares in Universal Health Services (NYSE:UHS) during the second quarter, valued at approximately $83.33 million, representing 0.71% ownership. The company reported strong Q2 earnings, beating analyst estimates with EPS of $5.69 and revenue of $4.50 billion. Analysts maintain a "Hold" rating with a consensus target price of $234.14, and the company has declared a quarterly dividend of $0.20 per share.

**4. Panagora Asset Management Inc. Decreases Stock Position in Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251205T230904 | Somewhat-Bullish | Relevance: 95%
- Panagora Asset Management Inc. significantly cut its stake in Universal Health Services, Inc. (NYSE:UHS) by 95% in the second quarter, selling over 153,000 shares. Despite this, Universal Health Services reported strong quarterly earnings and revenue, exceeding analyst expectations, and maintains high institutional ownership. The article also details other institutional investment changes, insider transactions, and recent analyst ratings for UHS.

**5. HCAâ€™s Cash Machine Looks Cheap After A Healthy Run**
- Source: Finimize | 20251203T145120 | Neutral | Relevance: 73%
- HCA Healthcare, the largest for-profit hospital operator in the U.S., has shown strong recent performance with a 56.6% total return over 12 months and raised full-year guidance for 2025. Despite policy risks and labor cost inflation, its robust cash generation, strong margins, and perceived valuation discount make it an appealing opportunity for long-term investors, though the stock carries risks associated with leverage and regulatory uncertainty.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Guggenheim | $274 | $253 | +8% |
| 2025-11-13 | Wells Fargo | $259 | $249 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Guggenheim | main | Buy |
| 2025-11-13 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($11.07M) |
| Sells | 3 ($30.51M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-3.4%)
- First Eagle Investme: 8.4% (+0.0%)
- Blackrock Inc.: 8.0% (-11.9%)
- State Street Corpora: 4.7% (-3.1%)
- FMR, LLC: 3.8% (+0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.5% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $31M sold (3 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.87 elevated, pricing in significant growth expectations. Analyst sentiment positive (2 raises, avg +6%). Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.5B |
| Beta | 1.27 |
| 52W Range | $152.33 - $246.33 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.87 |
| Forward P/E | 9.8 |
| Current P/E | 10.6 |
| YoY Growth | 8.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 3.0% to -2.5% (-5.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.22x) but short-term weakness (below SMA20). MACD histogram bearish (-1.34), momentum weakening. RSI neutral at 54. OFD pattern: -MLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.53% (CS: 32) | Weak |
| RSI_14 | 53.6 | Neutral |
| MACD Histogram | -1.34 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 1.222x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $231.08
- **Stop Loss:** $218.78 (5.3% risk)
- **Target:** $243.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $9,243.20
- **Portfolio %:** 9.24%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-25 (Est: $5.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.95 | $5.69 | +14.9% |
| 2025Q2 | $4.96 | $5.35 | +8.0% |
| 2025Q1 | $4.36 | $4.84 | +11.1% |
| 2024Q4 | $4.18 | $4.92 | +17.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*